Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio
Bristol-Myers Squibb (BMY) moved to expand its reach into cancer-fighting drugs by buying Mirati Therapeutics (MRTX) in an all-cash deal for what could total $5.8 billion.
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal
Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B
Bristol-Myers Squibb (BMY) agreed to buy cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 billion. The deal will help Bristol-Myers Squibb bring new drugs into their pipeline as some of t...
Bristol-Myers Squibb enhances oncology portfolio in deal worth up to $5.8bn
Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the cancer drug developer at up to $5.8 billion. This acquisition aims to divers...
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion
The acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb's best-selling products.
Bristol-Myers Squibb enahnces oncology portfolio in deal worth up to $5.8bn
Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the cancer drug developer at up to $5.8 billion. This acquisition aims to divers...
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
Bristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion.
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
The deal expands the pharmaceutical company's portfolio of cancer drugs.
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
The risk to the market is mounting, and with it, volatility. The VIX is up nearly 50% in the last month and heading higher, which means the S&P 500 could be heading lower.
Drugmakers agree to participate in Medicare price negotiations
Major drugmakers including Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Merck & Co Inc (NYSE:MRK) have agreed to participate in the Inflation Reduction Act's (IRA's) Medicare Drug ...
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500.
Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years
Since Bristol Myers Squibb acquired Celgene for $74 billion in 2019, the stock price has faced challenges and stagnation. The company's defensive strategy to defend the value of its legacy products...
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
Healthcare stocks generally offer a lot of upside. The cost of healthcare is incredibly expensive in the United States and the companies that deliver it tend to do very well overall.
Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study
Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.
Related Companies